



Rob Frohn, CFO

Q1 2007 Results

“Fit for the future”

April 24, 2007

- Autonomous growth of Coatings/ Chemicals 6%
- EBITDA up 10% to 307 million
- Net income EUR 246 million
- EUR 11 billion cash deal for Organon BioSciences announced
- EUR 1.6 billion share buyback starting May 3, 2007




Q1 OPERATIONAL PERFORMANCE



EUR mln	Q1 2007	Δ%
Revenues Coatings/Chemicals	2,501	1
EBITDA* Coatings/Chemicals	307	10
EBIT* Coatings/Chemicals	219	18
Net income* Coatings/Chemicals	133	18

Ratio Coatings/Chemicals	2007	2006
EBITDA margin*, in %	12.3	11.3
EBIT margin*, %	8.8	7.5

* Before incidentals



Coatings – higher EBITDA margin on 8% growth



- Revenues up driven by 8% autonomous growth
- Acquisitions adding 4% offset by currencies
- EBITDA up 11%
- European business improving; strong growth in emerging markets
- Continued raw material price pressure – particularly in industrial businesses



- Decorative Coatings
 - promising start, better European conditions
 - review roadmap for further improvement
- Industrial activities – solid results
- Marine & Protective – driven by Aerospace and Protective
- Car Refinishes – strong performance in Europe and Asia



EUR mln	Q1 2007	Δ%
Revenues	1,554	8
EBITDA*	153	11
EBIT*	117	13

Ratio	2007	2006
EBITDA margin*, in %	9.8	9.6
EBIT margin*, %	7.5	7.3

* Before incidentals.

Chemicals: Woodchips as fuel



Chemicals – strong EBITDA margin on 4% growth

- Autonomous growth of 4%; negative currency impact of 2%
- Strong margin management contributed to higher EBIT
- EBITDA margin of 17.9%
- Raw materials and energy pressure successfully countered
- Strong performance across all business areas



- Pulp & Paper Chemicals
 - solid results on higher prices in bleaching chemicals
 - benefit from hydrogen peroxide JV in U.S.
- Base Chemicals – robust performance Chlor Alkali
- Functional Chemicals – good start, production issue resolved
- Surfactants – higher on strong demand in Agro and Mining business
- Polymer Chemicals – income up on savings and margin management



<i>EUR mln</i>	Q1 2007	Δ%
Revenues	917	1
EBITDA*	164	1
EBIT*	115	6

<i>Ratio</i>	2007	2006
EBITDA margin*, in %	17.9	17.9
EBIT margin*, %	12.5	11.8

*Before incidentals.



<i>EUR mln</i>	Q1 2007	Δ%
Revenues	920	-
EBIT*	147	4

<i>Ratio</i>	2007	2006
EBIT margin*, in %	16.0	15.4
S&D in % revenues	29.6	29.7
R&D in % revenues	15.4	16.5

* *Before incidentals.*



- Organon strong performance of key products, 4% autonomous growth
- Operating income Organon before incidentals EUR 84 million
- Record quarter for Intervet; EBIT margin of 21.7%
- 12% autonomous growth at Intervet



Q1 FINANCIAL PERFORMANCE

Strong financial position further improved



<i>End March '07/ End '06, EUR mln</i>	2007	2006
Equity	4,513	4,263
Net borrowings	955	1,090
Gearing (ratio)	0.21	0.26

<i>Q1 ratios</i>	2007	2006
Interest coverage	7.9	6.8

Share buyback

- EUR 1.6 billion share buyback program
- Open market program
- Commencing May 3, completion expected by end 2007
- Subject to shareholder approval, shares will be cancelled



AGENDA 2007



- Accelerate growth across portfolio
- Improve margins in mature markets
- Active consolidator in a financially disciplined manner
- Transfer of Organon BioSciences



- Well positioned for profitable growth
- Outgrow our markets and improve financial returns



Q1 2007 Results

“Strong quarter for the new Akzo Nobel”

Q&A

April 24, 2007



Safe Harbor Statement*



This presentation contains statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

**Pursuant to the U.S. Private Securities Litigation Reform Act 1995.*